Rosalind Advisors Inc. Buys 312,500 Shares of Trevi Therapeutics, Inc. (NASDAQ:TRVI)

Rosalind Advisors Inc. raised its stake in Trevi Therapeutics, Inc. (NASDAQ:TRVI - Free Report) by 41.7% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 1,062,500 shares of the company's stock after acquiring an additional 312,500 shares during the quarter. Trevi Therapeutics comprises 2.2% of Rosalind Advisors Inc.'s holdings, making the stock its 17th largest position. Rosalind Advisors Inc. owned 1.38% of Trevi Therapeutics worth $4,378,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds have also recently bought and sold shares of the stock. Geode Capital Management LLC grew its position in shares of Trevi Therapeutics by 10.2% in the third quarter. Geode Capital Management LLC now owns 1,264,166 shares of the company's stock valued at $4,223,000 after purchasing an additional 117,418 shares during the last quarter. State Street Corp grew its holdings in Trevi Therapeutics by 5.9% in the 3rd quarter. State Street Corp now owns 952,912 shares of the company's stock valued at $3,183,000 after buying an additional 53,051 shares in the last quarter. Acuta Capital Partners LLC increased its position in Trevi Therapeutics by 11.7% during the 3rd quarter. Acuta Capital Partners LLC now owns 290,500 shares of the company's stock worth $970,000 after buying an additional 30,500 shares during the period. Charles Schwab Investment Management Inc. lifted its holdings in shares of Trevi Therapeutics by 14.7% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 173,063 shares of the company's stock worth $713,000 after buying an additional 22,145 shares in the last quarter. Finally, Bank of New York Mellon Corp lifted its holdings in shares of Trevi Therapeutics by 2.1% during the fourth quarter. Bank of New York Mellon Corp now owns 140,219 shares of the company's stock worth $578,000 after buying an additional 2,935 shares in the last quarter. 95.76% of the stock is currently owned by institutional investors and hedge funds.

Remove Ads

Analyst Ratings Changes

A number of equities analysts recently commented on TRVI shares. HC Wainwright reaffirmed a "buy" rating and set a $12.50 price target on shares of Trevi Therapeutics in a research report on Wednesday, March 19th. D. Boral Capital restated a "buy" rating and set a $21.00 target price on shares of Trevi Therapeutics in a research report on Wednesday, March 19th. Oppenheimer lifted their price target on shares of Trevi Therapeutics from $12.00 to $20.00 and gave the company an "outperform" rating in a research report on Tuesday, March 11th. B. Riley reissued a "buy" rating and set a $20.00 price target (up previously from $11.00) on shares of Trevi Therapeutics in a research report on Wednesday, March 19th. Finally, Needham & Company LLC dropped their price objective on Trevi Therapeutics from $25.00 to $24.00 and set a "buy" rating for the company in a report on Wednesday, March 19th. Seven analysts have rated the stock with a buy rating and three have issued a strong buy rating to the stock. Based on data from MarketBeat, Trevi Therapeutics currently has a consensus rating of "Buy" and an average target price of $17.56.

Insider Buying and Selling at Trevi Therapeutics

In related news, insider Farrell Simon sold 81,313 shares of the business's stock in a transaction on Monday, March 10th. The stock was sold at an average price of $6.75, for a total transaction of $548,862.75. Following the sale, the insider now owns 76,900 shares in the company, valued at $519,075. The trade was a 51.39 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, CEO Jennifer L. Good sold 5,263 shares of the company's stock in a transaction dated Friday, March 21st. The stock was sold at an average price of $6.58, for a total value of $34,630.54. Following the completion of the transaction, the chief executive officer now directly owns 213,313 shares of the company's stock, valued at approximately $1,403,599.54. The trade was a 2.41 % decrease in their position. The disclosure for this sale can be found here. Company insiders own 24.37% of the company's stock.

Trevi Therapeutics Trading Down 2.1 %

Trevi Therapeutics stock traded down $0.14 during midday trading on Wednesday, reaching $6.47. The company's stock had a trading volume of 1,059,555 shares, compared to its average volume of 997,739. The stock has a market cap of $625.53 million, a PE ratio of -14.70 and a beta of 0.90. Trevi Therapeutics, Inc. has a 52 week low of $2.30 and a 52 week high of $7.39. The business has a 50-day moving average price of $4.70 and a 200-day moving average price of $3.81.

Trevi Therapeutics (NASDAQ:TRVI - Get Free Report) last posted its quarterly earnings results on Tuesday, March 18th. The company reported ($0.11) earnings per share for the quarter, beating analysts' consensus estimates of ($0.12) by $0.01. As a group, research analysts predict that Trevi Therapeutics, Inc. will post -0.49 EPS for the current fiscal year.

Trevi Therapeutics Company Profile

Trevi Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapy Haduvio for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC) conditions targeting the central and peripheral nervous systems.